Drug target ranking for glioblastoma multiforme

BACKGROUND: Glioblastoma Multiforme, an aggressive primary brain tumor, has a poor prognosis and no effective standard of care treatments. Most patients undergoing radiotherapy, along with Temozolomide chemotherapy, develop resistance to the drug, and recurrence of the tumor is a common issue after...

Descripción completa

Detalles Bibliográficos
Autores principales: Saraf, Radhika, Agah, Shaghayegh, Datta, Aniruddha, Jiang, Xiaoqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074458/
https://www.ncbi.nlm.nih.gov/pubmed/33902757
http://dx.doi.org/10.1186/s42490-021-00052-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074458/
https://www.ncbi.nlm.nih.gov/pubmed/33902757
http://dx.doi.org/10.1186/s42490-021-00052-w

Ejemplares similares